Clin Psychopharmacol Neurosci.  2022 Aug;20(3):581-583. 10.9758/cpn.2022.20.3.581.

Aripiprazole Improved Post-Streptococcal Dyskinesia by Modulating Dopaminergic Activity: A Case Report

Affiliations
  • 1Department of Psychiatry, Chung-Ang University College of Medicine, Seoul, Korea
  • 2Department of Nuclear Medicine, Chung-Ang University Hospital, Seoul, Korea

Abstract

This case report aimed to discuss the efficacy of aripiprazole for dyskinesia in patients with functional movement disorder after streptococcal infection, with its biological action of modulating dopamine hyperactivity in the basal ganglia as a dopamine partial agonist. This report has shown that the [18F] N ‐(3‐Fluoropropyl)‐2β‐carbon ethoxy‐3β‐(4‐iodophenyl) nortropane positron emission tomography findings of the patient revealed that the dopamine hyperactivity in the basal ganglia at baseline was normalized after aripiprazole treatment due to its balancing effect as a dopamine partial agonist.

Keyword

Aripiprazole; Streptococcal infection; Dyskinesia; Basal ganglia; Dopamine
Full Text Links
  • CPN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr